» Educational Qualifications

» Academic Titles

» Publications

SCI-SSCI or SCI Expanded Articles

  • Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κB. Erdogan S, Turkekul K, Dibirdik I, Doganlar ZB, Doganlar O, Bilir A. Invest New Drugs. 2019 Apr 16. doi: 10.1007/s10637-019-00774-8. (April 2019)
    1
    ATIF
  • Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway. Erdogan S, Turkekul K, Dibirdik I, Doganlar O, Doganlar ZB, Bilir A, Oktem G. Biomed Pharmacother. 2018 Nov;107:793-805. doi: 10.1016/j.biopha.2018.08.061. Epub 2018 Aug 22. (December 2018)
    12
    ATIF
  • Downregulation of midkine enhances the efficacy of quercetin on androgen-sensitive prostate cancer stem cell survival through arresting cell cycle and inducing apoptosis. Erdogan S, Turkekul K, Serttas, R, Doganlar, Z. B., Doganlar O, Dibirdik I, Bilir A. FEBS OPEN BIO   2018, 8(1): 327 (July 2018)
  • Investigation of the possible role of luteolin in breast cancer. Erbas H, Kandemir N, Dibirdik I, Aydogdu N, Cakir E. FEBS JOURNAL  283 (SI-S1): 263; 2016     (October 2016)
  • The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-κB signaling. Erdogan S, Doganlar O, Doganlar ZB, Serttas R, Turkekul K, Dibirdik I, Bilir A. Life Sci. 2016, 162:77-86 (August 2016)
    28
    ATIF
  • The flavonoid apigenin reduces survival and migration of CD44+ prostate cancer stem cells. S. Erdogan, O. Doganlar, Z. B. Doganlar, R. Serttas, K. Turkekul, I. Dibirdik, A. Bilir. FEBS JOURNAL 283 (SI-S1): 299; 2016.
  • Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia. Uckun FM, Qazi S, Dibirdik I, Myers DE. Integr Biol (Camb). 2013; 5(1):122-32 (May 2013)
    5
    ATIF
  • In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton’s tyrosine kinase and Polo-like kinases, against human leukemic B-cell precursors. Uckun FM, Dıbırdık I, Sarkissian A and Qazi S. Drug Research/Arzneimittelforschung 2011; 61(4): 252-9.
    1
    ATIF
  • CD22 exon 12 deletion as a pathogenic mechanism of human B-precursor leukemia. Uckun FM, Goodman P, Ma H, Dıbırdık I, Qazi S. Proceedings of the National Academy of Sciences (PNAS), 2010; 07(39): 16852-7. (September 2010)
    7
    ATIF
  • Augmentation of the anti-leukemic potency of total body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK). Uckun FM, Dıbırdık I, Qazi S. Radiation Research, 2010; 174(4): 526-31.
  • Chemoprevention of colorectal cancer by targeting Janus Kinase 3 with a rationally designed small molecule inhibitor. Uckun FM, Dıbırdık I. Nutrition and Cancer, 2010; 62 (7): 968-972.
  • Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF-receptor kinase. Uckun FM, Dıbırdık I, Qazi S. Drug Research / Arzneimittelforschung 2010; 60(4): 218-225.
  • Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B lineage ALL cells. Uckun FM, Dıbırdık I, Qazi S, Yiv S. Drug Research/Arzneimittelforschung 2010; 60(4): 210-217.
  • Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors. Uckun FM, Vassilev A, Dıbırdık I, Tibbles H. Anticancer Agents Med. Chem. 2007; 7(6): 612-23. (November 2007)
    2
    ATIF
  • Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Uckun FM, Dıbırdık I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH. Bioorg Med Chem. 2007;15 (2):800-14. (January 2007)
    8
    ATIF
  • Anti-cancer activity profile of 3'-azidothymidine 5'-[p-methoxyphenyl methoxyalaninyl phosphate] (Compound 003), a novel nucleoside analog. Uckun FM, Vassilev AO, Dıbırdık I, Liu XP, Erbeck D, Tibbles HE, Qazi S, Venkatachalam TK. Drug Research /Arzneimittelforschung. 2004;54(11):715-31.
  • In vitro and in vivo pharmacokinetic features and metabolism of the novel cytotoxinucleoside analog 3'-azidothymidine 5'-[p-methoxyphenyl methoxyalaninyl phosphate] (Compound 003). Uckun FM, Chen CL, Liu XP, Dıbırdık I, Venkatachalam TK. Drug Research / Arzneimittelforschung. 2004 ; 54(11): 732-45.
  • Stimulation of Bruton's Tyrosine kinase (BTK) and inositol 1,4,5-trisphosphate production in leukemia and lymphoma cells exposed to low-energy electromagnetic fields. Dıbırdık I, Bofenkamp M, Skeben P, Uckun FM. Leukemia and Lymphoma 40(1-2):149-156, 2000.
    1
    ATIF
  • Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. Malaviya R, Zhu D, Dıbırdık I, Uckun FM. J Biol Chem., 274(38): 27028-38, 1999.
    15
    ATIF
  • Stimulation of Src family protein tyrosine kinases as a proximal and mandatory step for Syk kinase-dependent phospholipase C gamma 2 activation in lymphoma-B cells exposed to low energy electromagnetic fields. Dıbırdık I, Kristupaitis D, Kurosaki T, Tuel-Ahlgren L, Chu A, Pond D, Tuong D, Luben R, Uckun FM. J.Biol. Chem., 273(7): 4035-4039,1998.
    3
    ATIF
  • TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus. Uckun FM, Chelstrom LM, Tuel-Ahlgren L, Dıbırdık I, Irvin JD, Langlie MC, Myers DE. Antimicrob. Agents Chemother., 42(2):383-388, 1998.
    3
    ATIF
  • Signal-transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. Uckun FM, Burkhardt AL, Jarvis L, Jun X, Stealey B, Dıbırdık I, Myers DE, Tuel Ahlgren L, Bolen JB. J. Biol. Chem., 268(28): 21172-21184, 1993.
    1
    ATIF
  • Interleukin-3 stimulation enhances tyrosine phosphorylation and proliferative activity of human fetal thymocytes and leukemic T-cell precursors at multiple developmental stages of Bcell ontogeny. Uckun FM, Hanson M, Tuel-Ahlgren L, Dıbırdık I, Chandan-Langlie M, Discher D, Obuz V, Schieven GL, Ledbetter JA. Leukemia and Lymphoma, 6:117-132, 1992.
  • Interleukin-7 receptor engagement stimulates tyrosine phosphorylation, inositol phospholipid turnover, proliferation, and selective differentiation to the CD4 lineage by human fetal thymocytes. Uckun FM, Tuel-Ahlgren L, Obuz V, Smith R, Dıbırdık I, Hanson M, Langlie MC, Ledbetter JA. Proc. Natl. Acad. Sci. USA, 88:6323-6327, 1991.
    2
    ATIF
  • T lenfositlerinin prereplikatif fazında kalsiyum ve kalmodulinin önemi Kutluay T, Dıbırdık I, Kisa U, Karaca L. Turkish Journal of Biochemistry, 15(2): 13-23, 1990.
  • Engagement of interleukin-7 receptor stimulates tyrosine phosphorylation, phosphoinositide turnover, and clonal proliferation of human T-lineage acute lymphoblastic leukemia cells. Dıbırdık I, Chandan-Langlie M, Ledbetter JA, Tuel-Ahlgren L, Obuz V, Waddick KG, Gajl-Peczalska K, Schieven GL, Uckun FM. Blood, 78(3):564-570, 1991.
    3
    ATIF
  • Interleukin-7 receptor ligation stimulates tyrosine phosphorylation, inositol phospholipid turnover, and clonal proliferation of human B-cell precursors. Uckun FM, Dıbırdık I, Smith R, Tuel-Ahlgren L, Chandan-Langlie M, Schieven GL, Waddick KG, Hanson M, Ledbetter JA. Proc. Natl. Acad. Sci. USA, 88: 3589-3593, 1991.
  • Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases by the Pan-B-cell receptor CD40/Bp50 at discrete developmental stages of human B-cell ontogeny. Uckun FM, Schieven GL, Dıbırdık I, Chandan-Langlie M, Tuel-Ahlgren L, Ledbetter J. J. Biol. Chem., 266(2): 17478-17485, 1991.
  • Yanık hastalarında hümoral immune sistem komponentleri ve B hücre fonksiyonları. Dıbırdık I, Durak N, Kisa U, Kilinc C, Bingöl NK, Karayilanoglu T, Erbil K, Kutluay T, Aytemiz C, Karaca L. Turkish Journal of Biochemistry, 1: 79-89, 1993.
  • Expression and function of low molecular weight B-cell growth factor receptors on B-cell precursor acute lymphoblastic leukemia cells. Dıbırdık I, Uckun FM, Kutluay T, Karaca L. Turkish Journalof Biochemistry, 18(1): 69-78, 1993.
  • Early B-cell precursors express functional receptors for human interleukin-7: Ligation of human interleukin-7 receptors with recombinant human interleukin- 7 results in an increased proliferation index. Dıbırdık I, Bingol NK, Kilinc C, Dibirdik LJ, Kurt I, Kutluay T, Karaca L, Uckun FM. Doga-Tr.J.of Medical Sciences, 18:103-113, 1993.
  • Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis. Waddick KG, Chae HP, Tuel-Ahlgren L, Jarvis LJ, Dıbırdık I, Myers DE, Uckun FM. Radiat. Res., 136: 313-319, 1993.
  • Tyrosine phosphorylation is a mandatory proximal step in radiation-induced activation of the protein kinase C signalling pathway in human B-lymphocyte precursors. Uckun FM, Schieven GL, Tuel-Ahlgren L, Dıbırdık I, Myers DE, Ledbetter JA, Song CW. Proc. Natl. Acad. Sci. USA, 90: 252-256, 1993.
  • Increased urinary hydroxyproline / creatinine and calcium / creatinine ratios in oophorectomized women. Kilinc C, Dıbırdık I, Yilmaz K, Kutluay T, Karaca L. Doga-Tr. J. of Medical Sciences, 17: 177-183, 1993.
  • The ligation of interleukin-7 receptors on human B-cell precursors by recombinant interleukin-7 results in clonal proliferation by increasing the intracellular calcium concentration. Dıbırdık I, Kilinc C, Bingol NK, Dibirdik LJ, Kurt I, Kutluay T, Karaca L, Uckun FM. Doga- Tr.J.of Medical Sciences, 18:91-101, 1993.
  • Effects of prophylactic intravenous immunoglobulin-G therapy on humoral and cellular immune components and their functions in burned patients. Dıbırdık I, Durak N, Kislaoglu E, Kutluay T, Aytemiz C. Burns, 21(2):130-135, 1995.
  • The development and validation of a competitive, microtiter plate enzymeimmunoassay for human albumine in urine. Akman A, Kurt I, Gultepe M, Dıbırdık I, Kilinc C, Kutluay T, Karaca L, Bingol NK. Journal of Immunoassay and Immunochemistry, 16(3): 279-296, 1995.
    2
    ATIF
  • Effect of force-feeding on fatty liver production and some blood parameters of native and Romanov geese. Muglalli OH, Ergun A, Dogan S, Dıbırdık I, Nazaroğlu NK, Güler A, Oba G. Tr.J.of Veterinary and Animal Sciences, 21:107-113, 1997.
  • Electromagnetic field-induced stimulation of Bruton's tyrosine kinase. Kristupaitis D, Dıbırdık I, Vassilev A, Mahajan S, Kurosaki T, Chu A, Tuel-Ahlgren L, Tuong D, Pond D, Luben R, Uckun FM. J Biol Chem., 273(20):12397-401, 1998.
    1
    ATIF

International Articles

  • Preclinical and First-In-Human Phase I Clinical Evaluation of Stampidine, a Potent Anti-HIV. Cahn P, Rolon MJ, Gun AM, Ferrari I, Dibirdik I, Qazi S, D'Cruz O, Sahin K, Uckun F. Journal of AIDS & Clinical Research 3: 138.doi:10.4172/2155-6113.1000138; 2012
    5
    ATIF
  • In vivo anti-cancer activity of a liposomal nanoparticle construct of multifunctional tyrosine kinase inhibitor 4-(4’-hydroxyphenyl)-amino-6, 7-dimethoxyquinazoline. Dıbırdık I, Yiv S, Qazi S, Uckun FM. J Nanomedic Nanotechnol 2010; 1 (1): 001-004.
    1
    ATIF
  • Demir eksikligi anemili hasta lenfositlerinde fitohemaglutinine yanit. Kutluay T, Dıbırdık I, Kısa U, Karaca L. Turkish Journal of Biochemistry, 15(2): 25-32, 1990.
  • Alpha-tocopherol and gingko biloba treatment protects lipid peroxidation during ischemic period in rat groin island skin flaps. Deveci M, Dıbırdık I, Celiköz B, Selmanpakoglu N, Kisa U. Eur. J. Plastic Surgery, 20:141-144,1997.

International Conference Proceedings

  • Cetuximab and ABS interacts synergistically for the inhibition of HT-29 colorectal cancer cell line proliferation (November 2018)
  • Combination of ABS and Cisplatin has Potent and Synergistic Activity Against MCF-7 Human Breast Cancer Cells. Cigdem FIDAN, Busra DILER ZENGINER, Ilker DIBIRDIK Union of Thrace Universities 2nd International Health Sciences Congress. 15-17 November 2018, Tekirdağ, Turkey. (November 2018)

International Conferences and Symposiums

  • Gallic acid, a natural polyphenolic acid, inhibits the growth of HT-29 human colon adenocarcinoma cells in vitro. ÖZER BO, DIBIRDIK İ. 2nd International Conference on “Veterinary Biochemistry and Clinical Biochemistry. OCTOBER 24-26, 2019 ANKARA / TURKEY. P-3; pg 51. (October 2019)

National Articles

  • Vanillin: is it just an aromatic or a cure for cancer? Mutlu AU, Kanev M, Zenginer BD, Dıbırdık İ. Turkish Med Stud J. 2019;6(3):85-9. (October 2019)
  • Yanık hastalarında hücresel immune sistemö lenfosit fenotipiö blastik yetenek ve alloreaktivite. Dıbırdık I, Durak N, Kisa U, Yilmaz K, Aytemiz C, Karaca L. Optimal Tıp Dergisi 6(3): 107-111, 1993.
  • Experimental evaluation of the efficiency of hyperfractioned total body irradiation as a conditioning regimen for bone marrow transplantation. Beyzadeoglu M, Elci H, Pak Y, Pak I, Dirican B, Dıbırdık I. Turkish J. Cancer, 25(2): 65-73 1995.

Master`s Theses Advised

  • SEZEN ÇOLAKOĞULLARI
  • Nihayet KANDEMİR

Referee Positions

  • Balkan Medical Journal. Manuscript No: BalkanMedJ-2019-9-91 (December 2019)
  • TUBAP 2017/217 Sonuç raporu (November 2019)
  • TUBAP 2018/197 - 3. ara rapor (October 2019)
  • TUBAP 7415 (September 2019)
  • TUBAP 2017/217 3. Ara Rapor (June 2019)
  • Balkan Medical Journal. Manuscript No: BalkanMedJ-2019-3-26  (May 2019)
  • Balkan Medical Journal. Manuscript No: BalkanMedJ-2019-1-64 (April 2019)
  • TUBAP 2018/197 - 2. ara rapor (February 2019)
  • TUBİTAK 1512 #2150139 (GR, SR)
  • TUBİTAK 1001 #217S571
  • TUBİTAK 1001 #217S833
  • TUBİTAK 1001 #217S518
  • TUBİTAK 1005 #217S380
  • TUBİTAK 2515 COST - 216S085
  • TUBİTAK 1001 #218S558
  • TUBİTAK 1001 #218S514
  • TUBİTAK 1001 #218S710
  • TUBİTAK 1001 #218S554
  • TÜBAP-2016/42 (2.GR, SR)
  • TÜBAP-2018/197
  • TÜBAP-2017/71 (SR)
  • TÜBAP-2017-123  (2.GR)
  •  TÜBAP-2017-217 (2.GR) 
  • TUBİTAK 1005 #217S380

Projects

  • Kurkuminin Diyetsel Karnitin Kaynaklı TMAO ile Değiştirilmiş Kardiyovasküler Parametreler Üzerindeki Etkisi (TÜBAP #2018/369) (December 2018)
  • Konvansiyonel prostat kanser kemoterapisinde kanser kök hücre seçici tedavi modalite geliştirilmesinde salinomisinin in vitro değerlendirilmesi (TÜBAP) (November 2018)
  • HT29 İnsan Kolon Kanser Modeli İle Yeni Terapötik Modalitelerin Geliştirilmesi (TÜBAP #2017/222) (December 2017)